PURPOSE: To develop a two-dimensional simulation platform for the transport of @entity632 to the @entity157 . To examine the temporal and spatial variation of @entity632 concentration and its penetration into the @entity5 and the surrounding normal tissues. METHODS: Simulations are carried out with Fluent/UNS using the finite volume method to obtain the interstitial fluid pressure, velocity, and concentration profiles. RESULTS: Interstitial fluid pressure in the @entity5 and core reaches a steady state value in about 800 s, corresponding well with the assumed time scale for interstitial matrix fluid percolation (-1,000 s). There is a strong correlation between the drug concentration in the interstitial space of @entity5 and blood plasma for time > 1 h. Concentration of @entity632 is highest in the viable zone of the @entity5 at early times and in the @entity39 core at later times, and lowest in the surrounding normal tissues. Diffusion is the dominant form of transport for @entity632 . CONCLUSIONS: Varying the volume of solution injected, while keeping the dosage the same, does not cause significant changes in the amount and distribution of drug in the @entity5 . A higher vascular exchange area leads to higher concentrations of drug in the @entity5 . Lymphatic @entity5 causes negligible reductions in the mean concentrations in all three different zones. Cellular metabolism and DNA binding kinetics decrease the mean concentrations of drug by about 15 to 40%, as compared to the baseline case.

Simulation of the delivery of XXXX to @entity157 .

@entity632 :: ('MESH:D004317', 'Chemical') :: ['doxorubicin'] @entity157 :: ('MESH:D006528', 'Disease') :: ['hepatoma'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'drainage in the tumor'] @entity39 :: ('MESH:D009336', 'Disease') :: ['necrotic']
@entity632 :: (MESH:D004317,Chemical) :: ['doxorubicin']
